AI Article Synopsis
- A20, encoded by TNFAIP3, is a key negative regulator of immune activation, functioning as a ubiquitin editing enzyme to modulate various immunologic pathways.
- A20's effects vary significantly depending on cell types and disease models, highlighting its complex role in immunomodulation.
- Mutations and germline variants of A20 are linked to inflammatory diseases and B cell lymphomas, with recent findings on A20 haploinsufficiency revealing its critical impact on immune function and diverse clinical manifestations.
Article Abstract
A20, encoded by TNFAIP3, is a critical negative regulator of immune activation. A20 is a ubiquitin editing enzyme with multiple domains, each of which mediates or stabilizes a key ubiquitin modification. A20 targets diverse proteins that are involved in pleiotropic immunologic pathways. The complexity of A20-mediated immunomodulation is illustrated by the varied effects of A20 deletion in different cell types and disease models. Clinically, the importance of A20 is highlighted by its extensive associations with human disease. A20 germline variants are associated with a wide range of inflammatory diseases, while somatic mutations promote development of B cell lymphomas. More recently, the discovery of A20 haploinsufficiency (HA20) has provided real world evidence for the role of A20 in immune cell function. Originally described as an autosomal dominant form of Behcet's disease, HA20 is now considered a complex inborn error of immunity with a broad spectrum of immunologic and clinical phenotypes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10875-024-01681-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!